Phase III Study of ASP2151 in Herpes Simplex Patients
Phase III Study of ASP2151 in Herpes Simplex Patients - A Double-blind, Placebo-controlled Study -
Sponsor: Maruho Co., Ltd.
A PHASE3 clinical study on Herpes Simplex, this trial is completed. The trial is conducted by Maruho Co., Ltd. and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maruho Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .